US Stock Movements: Beam Therapeutics surged on October 28 due to BEAM-301 clinical data and gene editing therapy
Bitget异动解读2026/10/28 16:11Beam Therapeutics October 28th Surge Analysis
Keywords: BEAM-301 clinical data, gene editing therapy
On October 27th, Beam released preliminary Phase I/II trial data for BEAM-301: in the 40mg dose group, two patients achieved 15 hours of controlled fasting with improved blood glucose management and no longer required starch supplementation after treatment; the 60mg dose group is currently enrolling, and the company plans to discuss potential approval pathways with the FDA.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google officially launches XREAL Aura
Google prices input tokens at $2 per million and output tokens at $10 per million.
Microsoft provides Copilot Harness through Microsoft Foundry
Crypto prices
More
